 |
Antithrombin III (AT III) is a blood protein that inhibits or stops the clotting factors in blood. Approximately 75% of the body's plasma coagulation inhibitory activity is derived from AT III.
AT III deficiency is a rare, inherited or spontaneously occurring condition that affects one in every 2,000 to 5,000 males and females worldwide. Individuals with this condition lack the AT III protein and spontaneous clotting can occur in the legs, arms, intestines, brain, kidney, eye, or other organs, such as the heart and lungs, as a result of normal, daily activity. In individuals with AT III deficiency, these clots can damage vital organs.
Thrombate III®, Antithrombin III (Human) is a sterile, nonpyrogenic, stable, lyophilized preparation of purified human antithrombin III (AT III).
US residents, refer to the WARNINGS section of the Thrombate III®, Antithrombin III (Human) package insert (PDF).
Thrombate III®, Antithrombin III (Human) therapy has demonstrated a low occurrance of side effects. In clinical studies with Thrombate III®, Antithrombin III (Human), the most common side effects were dizziness, chest tightness, nausea, and a foul taste in mouth. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses, cannot be totally eliminated. Individuals who receive infusions of blood or blood plasma may develop signs and/or symptoms of some viral infections, particularly hepatitis C. US residents please see the Prescribing Information (PDF).
US residents, please click here to go to www.thrombate.com.
|
|
|
